| Identification | More | [Name]
PYRITHIOXIN | [CAS]
1098-97-1 | [Synonyms]
5-[[5-HYDROXY-4-(HYDROXYMETHYL)-6-METHYL-PYRIDIN-3-YL]METHYLDISULFANYLMETHYL]-4-(HYDROXYMETHYL)-2-METHYL-PYRIDIN-3-OL
PYRITHIOXIN
PYRITHIOXINE
PYRITINOL
3,3’-(dithiobis(methylene))bis(5-hydroxy-6-methyl-4-pyridinemethano
3,3’-(dithiobis(methylene))bis(5-hydroxy-6-methyl-4-pyridinemethanol)
3,3’-(dithiodimethylene)bis(5-hydroxy-6-methyl-4-pyridinemethano
biocefalin
bonol
dipyridoxolyldisulfide
encefabol
epocan
pyridoxine-5-disulfide
pyridoxinedisulfide
vitaminb6disulfide
bis(5-hydroxy-4-hydroxymethyl-6-methyl-3-pyridylmethyl) disulphide
pyrithioxin free base
Bis-[(3-Hydroxy-4-Hydroxymethyl-2-Methyl-5-Pyridyl)-Methyl]-Disulfide
PYRITINOL (PYRITHIOXINE) BASE
PYRITINOL (PYRITHIOXINE) HCL | [EINECS(EC#)]
214-150-1 | [Molecular Formula]
C16H20N2O4S2 | [MDL Number]
MFCD00151477 | [Molecular Weight]
368.47 | [MOL File]
1098-97-1.mol |
| Chemical Properties | Back Directory | [Melting point ]
218-220° | [Boiling point ]
742.8±60.0 °C(Predicted) | [density ]
1.448±0.06 g/cm3(Predicted) | [storage temp. ]
Keep in dark place,Inert atmosphere,Room temperature | [solubility ]
Soluble in DMSO | [form ]
neat | [pka]
9.31±0.10(Predicted) | [color ]
White to Light yellow to Light orange | [Merck ]
14,7996 | [CAS DataBase Reference]
1098-97-1(CAS DataBase Reference) |
| Hazard Information | Back Directory | [Uses]
cognition enhancer, nootropic | [Uses]
Pyritinol can be used as a nootropic used in the prevention and treatment of cerebrovascular diseases.
| [Definition]
ChEBI: Pyritinol is a member of methylpyridines. | [Brand name]
Biontabol;Bonifwn;Cefalogen;Cerebrotrofina;Cervitalin;Divalvon-d;Enbol;Encefort;Encerbrovit;Encerebron;Fulneurina;Geribolina;Gerontabol comp.;Juniormen;Leonar;Logos;Maind;Musa;Neuroxin;Piriditol;Piririomin;Piritinol;Piritiomin;Plenumil;Sawaxin;Scintidin;Tibased;Tomevit;Tonobrein;Tonomentis. | [World Health Organization (WHO)]
Pyritinol, which is claimed to promote the uptake of glucose in
the brain, is used in the treatment of cerebrovascular disorders. However, WHO is
not aware of controlled experimental data to show that it has any therapeutic effect. |
|
|